VAPA

Across TCGA pan-cancer cohorts, VAPA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VAPA data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher VAPA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated VAPA expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, CCRCC, and GBM are the cancer types where VAPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.791	0.475	.002	64	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	19	view →
GBM	DFS	Quartile	All	0.241	0.574	.004	7	view →
PDAC	DFS	Quartile	All	0.284	0.578	.002	7	view →
LSCC	DFS	Median	II,III,IV	0.974	0.874	.017	1	view →
LUAD	OS	Median	All	0.778	0.915	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VAPA–HNSC (DFS)

Open the HNSC breakdown →